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Acute administration of rt-PA for acute stroke in Pakistani
patients — what does the available evidence teach us?
Maria Khan, Ayeesha Kamran Kamal
Director Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Karachi, Pakistan.
The National Institute of Neurological Disorders
and Stroke rt-PA Stroke Study-NINDS rt-PA, European
Cooperative Acute Stroke Study ECASS III, AND
Japanese Alteplase Clinical Trial J-ACT.
Why are these studies important and
noteworthy?
Strokes are an important public health problem; about
two thirds of stroke mortality will now be borne by the
developing world. Up until late 80's no treatment was
available to improve the deficits once stroke had occurred.
The NINDs Trial was the first randomized controlled trial
undertaken to evaluate the efficacy of this agent. 
After NINDS, European investigators undertook
another trial to assess whether the benefit of alteplase could
be extended beyond the 3 hour period as in the NINDS trial.
Three such trials were undertaken, with different doses of
alteplase and using different time windows. ECASS III
finally showed benefit with the extended time window of up
to 4.5 hours.
After NINDS, the Japanese also set out to evaluate the
efficacy of alteplase (rt-PA) in their population. They showed
that a dose of 0.6mg/kg was just as efficacious and safe as the
original dose of 0.9 mg/kg used in the NINDS trial.
Although there is not a lot published about the
administration of acute thrombolysis for stroke in
Pakistan , studies show that despite the widespread
absence of acute ambulance services and education,
stroke is recognized early and about a quarter of the
patients in urban areas present within the time window
and are eligible for rt-PA. Additionally, the published
studies show that our symptomatic ICH rates are
unacceptably high-the reasons for which are yet to be
elucidated. Keeping this in mind, the Japanese trial is
particularly important as the risk of haemorrhage reported
in our population with the conventional 0.9mg/kg dose is
unacceptably high.
Who were the participants?
NINDS trial was carried out in two parts. Part 1
assessed whether alteplase had clinical activity and it
assessed changes in neurologic deficits at 24 hours after
stroke. Part 2 used four outcome measures to assess
different aspects of recovery and to judge whether there was
a sustained clinical benefit. NINDS included patients, who
had a clearly defined time of onset of stroke, were
presenting within three hours of onset, and had a deficit
measurable on the NIHSS and a CT head showing no
evidence of intracranial haemorrhage. Patients with
uncontrolled sugars, uncontrolled blood pressures, recent
surgeries, low platelets and bleeding diatheses or deranged
coagulations were excluded from the study. The average age
of patients in the trial was around 68 years, 42% were
females, and more than 60% were whites. What was of note
was the NIHSS score which was an average of 14 or 15 in
both parts, meaning that these were patients with
moderately severe strokes. Uncontrolled sugars were not an
issue, and the average blood glucose level was around 150
mg/dl in both parts.
ECASS III included patients from European
countries between ages 18-80 years, presenting within 3-
4.5 hours after stroke onset. The rest of the conditions
were the same except that they also excluded patients with
severe strokes (NIHSS >25) and those who had a
combination of prior stroke and Diabetes. The primary
efficacy end point was disability at day 90 as assessed by
Modified Rankin Scale. 821 patients were randomized,
418 to the alteplase arm and 403 to the placebo arm. There
were two significant differences in the active and placebo
groups, first was the NIHSS which was lower in the
alteplase group, and history of prior stroke which was also
significantly lower in the alteplase group. The median
NIHSS was lower in ECASS III overall compared with
NINDS study.
Japanese Alteplase Clinical Trial was conducted at
22 centers in Japan, and enrolled 103 patients. The
inclusion and exclusion criteria were similar to NINDS
except they excluded patients with CT evidence of early
ischaemic changes in a large territory, comatose state and
an mRS of > 2. The baseline characteristics were also similar
to the NINDS population, except that cardioembolic strokes
were more frequent, and the mean time from onset to
treatment was more in J-ACT then in the NINDS trial. There
was no control arm, and results were compared to the NINDS
placebo arm.
What was the intervention?
From January 1991 to October 1994, 624 patients
underwent randomization. For part 1, 144 patients were
assigned to the rt-PA group and 147 to the placebo arm. For
part 2, 168 patients were assigned to the rt-PA group and 165
to placebo. Alteplase was given at a dose of 0.9 mg/kg.
ECASS III also used alteplase at a dose of 0.9 mg/kg
given within 3 to 4.5 hours of stroke onset. 
J-ACT used alteplase at a dose of 0.6mg/kg given
within three hours of stroke onset in 103 patients. 
In all three trials use of anti thrombotics was
prohibited in the first 24 hours of treatment. 
What was the outcome?
In part 1 of the NINDS trial no statistically significant
differences were detected between groups in the primary
outcome (improvement by 4 or more points in the NIHSS
score or a complete resolution of the neurologic deficit). In
part 2 however, the number of patients with favourable
outcomes for each of the four primary outcome measures
(mRS, Barthel Index, NIHSS and Glasgow outcome scale)
three months after stroke was higher in the t-PA group than in
the placebo group. As evaluated by the global test statistic,
the odds ratio for a favourable outcome in the t-PA group was
1.7 (95 percent confidence interval, 1.2 to 2.6; P0.008). There
was also an 11 percent absolute (55 percent relative) increase
in the number of patients with an NIHSS score of 0 or 1 in the
alteplase group.
In ECASS III, for the primary end point (disability at
day 90), 219 of the 418 patients in the alteplase group (52.4%)
had a favorable outcome (defined as a score of 0 or 1 on the
modified Rankin scale) at three months, as compared with 182
of the 403 patients in the placebo group (45.2%). This
represented an absolute improvement of 7.2 percentage points
(odds ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.76;
relative risk, 1.16; 95% CI, 1.01 to 1.34; P = 0.04). The global
odds ratio for a favourable outcome was 1.28 (95% CI, 1.00 to
1.65; P<0.05), indicating that the odds for a favourable
outcome (the ability to return to an independent lifestyle) after
stroke were 28% higher with alteplase than with placebo.
In J-ACT, the proportion of favourable outcomes was
36.9%, well exceeding the predetermined threshold of 33.9%.
Concerning the secondary efficacy end points, 50 patients
(48.5%) had a BI of 95 to 100 at 3 months compared with
50% of the rt-PA arm and 38% of the placebo arm in the
NINDS study (part 2). Fifty-one patients (49.5%)
experienced improvement by 4 points or a decrease to 0
points on the NIHSS at 24 hours after stroke onset compared
with 47% of the rt-PA arm and 39% of the placebo arm in the
NINDS study (part 1).
What was the risk of haemorrhage and death?
In the NINDS trial, there was a significantly larger
proportion of patients with symptomatic intracranial
haemorrhage (p=0.001). 11 deaths were attributable to
intracerebral haemorrhage of which 9 occurred in the
alteplase arm. Serious systemic bleeding also occurred in the
alteplase group only and minor external bleeding was also
more common with alteplase (23% vs 3%). However,
mortality did not differ significantly between the two groups.
In ECASS III, the rate of symptomatic ICH was 2.4%
in the alteplase group but this was significantly greater than
the rate in the placebo arm (p=0.008). Also the rate of
intracranial haemorrhage overall was significantly greater in
the alteplase arm. However, there was no difference in
mortality between the two groups.
In J-ACT, 5.8% patients had symptomatic ICH which
was similar to the NINDS study. The overall mortality with
0.6mg/kg dose was 9.7% which was lower than the NINDS
figure of 10-17%.
What were the conclusions?
NINDS trial first established the efficacy of alteplase
(0.9mg/kg) for acute ischaemic strokes within three hours of
onset. ECASS III then demonstrated that the window for
alteplase administration can be safely extended to 4.5 hours
after onset, but only in patients without a combination of
previous stroke and Diabetes. J-ACT concluded that similar
benefits can be achieved at least in the Japanese population
with a lower dose of alteplase (0.6mg/kg). 
How does this impact our clinical practice?
Alteplase is being used in Pakistan for the past 5-6
years. Previously a dose of 0.9mg/kg was the standard of
care. However, a review from Pakistan was published in
September 2009. The authors reported the experience with
rtPA from two tertiary care hospitals. The complication rate
that was reported was much greater than what has been
reported from the NINDS study. The rate of fatal
haemorrhage was 14%, non fatal haemorrhage was 10% and
mortality was 19% which was much greater than the 13%
reported in the NINDS stroke study. In view of this high
complication rate, and the equally good results with the lower
dose of alteplase in the Japanese trial, we must also evaluate
the efficacy and safety of 0.6mg/kg dose in our population.
Also we have to be extra careful when considering patients
for this therapy, since DM is much more prevalent in our
population and uncontrolled sugars are the single most
important predictor of haemorrhagic transformation post rt-
PA. At the very least, rt-PA should be offered in centers with
experience with this therapy and the protocols in Pakistan
need to develop a means of controlling glucose variations in
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addition to Blood pressure fluctuations in these patients.
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